Home > Healthcare > Anti-retroviral Drugs Market

Anti-retroviral Drugs Market Share

Report ID: GMI8298
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Anti-retroviral Drugs Market Share

The competitive landscape of the market is characterized by the presence of established pharmaceutical companies vying for market share. Key players are engaging in strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their product portfolios. The companies are actively adopting a multi-pronged approaches to address the rising demand for effective anti-retroviral drugs.

Anti-retroviral Drugs Market Companies

Prominent players operating in the anti-retroviral drugs industry are as mentioned below:

AbbVie Inc.
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Cipla
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc.
Johnson and Johnson
Merck & Co, Inc.
Pfizer Inc.
Viatris Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Anti-retroviral drugs market size was USD 29.1 billion in 2023 and is expected to register 4.2% CAGR from 2024-2032 owing to the increased investment in research and development, and the emergence of multiple generic drug alternatives worldwide.

The multi-class combination segment reached USD 7.9 billion in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to the growing burden of HIV and new drug approvals.

Anti-retroviral drugs market from the branded segment held 67.2% share in 2023 and is expected to register a commendable CAGR from 2024-2032 due to ongoing advancements and innovation in the development, distribution, and utilization of branded antiretroviral drugs.

AbbVie Inc., Bristol-Myers Squibb Company, Cipla, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc., Johnson and Johnson, Merck & Co, Inc., Pfizer Inc., and Viatris Inc., are some of the major anti-retroviral drugs companies worldwide.